Selected research
Industry Research
Levetiracetam Industry Research Report 2026
Market perspective
The global Levetiracetam market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Levetiracetam is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Levetiracetam is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Levetiracetam is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Levetiracetam include Zhejiang Jingxin Pharmaceutical, Chongqing shenghuaxi Pharmaceutical, Eisai Inc, Salubris Pharmaceuticals, Sanofi, Novartis, Pfizer, GlaxoSmithKline and UCB Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Levetiracetam market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Levetiracetam Market by Company
Zhejiang Jingxin Pharmaceutical
Chongqing shenghuaxi Pharmaceutical
Eisai Inc
Salubris Pharmaceuticals
Sanofi
Novartis
Pfizer
GlaxoSmithKline
UCB Pharma
Levetiracetam Segment by Type
Injection Solution
Tablet
Oral Liquid
Levetiracetam Segment by Application
Myoclonic Treatment
Tonic-clonic Seizures Treatment
Others
Levetiracetam Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Levetiracetam market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Levetiracetam and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Levetiracetam.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Levetiracetam manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Levetiracetam by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Levetiracetam in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Injection Solution
- Tablet
- Oral Liquid
Applications
- Myoclonic Treatment
- Tonic-clonic Seizures Treatment
- Others
Companies covered
- Zhejiang Jingxin Pharmaceutical
- Chongqing shenghuaxi Pharmaceutical
- Eisai Inc
- Salubris Pharmaceuticals
- Sanofi
- Novartis
- Pfizer
- GlaxoSmithKline
- UCB Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Levetiracetam Market Size (2021-2032)
- 2.2.2 Global Levetiracetam Sales (2021-2032)
- 2.2.3 Global Levetiracetam Market Average Price (2021-2032)
- 2.3 Levetiracetam by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Injection Solution
- 2.3.3 Tablet
- 2.3.4 Oral Liquid
- 2.4 Levetiracetam by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Myoclonic Treatment
- 2.4.3 Tonic-clonic Seizures Treatment
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Levetiracetam Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Levetiracetam Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Levetiracetam Revenue of Manufacturers (2021-2026)
- 3.4 Global Levetiracetam Average Price by Manufacturers (2021-2026)
- 3.5 Global Levetiracetam Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Levetiracetam, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Levetiracetam, Product Type & Application
- 3.8 Global Manufacturers of Levetiracetam, Established Date
- 3.9 Global Levetiracetam Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Zhejiang Jingxin Pharmaceutical
- 4.1.1 Zhejiang Jingxin Pharmaceutical Company Information
- 4.1.2 Zhejiang Jingxin Pharmaceutical Business Overview
- 4.1.3 Zhejiang Jingxin Pharmaceutical Levetiracetam Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Zhejiang Jingxin Pharmaceutical Levetiracetam Product Portfolio
- 4.1.5 Zhejiang Jingxin Pharmaceutical Recent Developments
- 4.2 Chongqing shenghuaxi Pharmaceutical
- 4.2.1 Chongqing shenghuaxi Pharmaceutical Company Information
- 4.2.2 Chongqing shenghuaxi Pharmaceutical Business Overview
- 4.2.3 Chongqing shenghuaxi Pharmaceutical Levetiracetam Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Chongqing shenghuaxi Pharmaceutical Levetiracetam Product Portfolio
- 4.2.5 Chongqing shenghuaxi Pharmaceutical Recent Developments
- 4.3 Eisai Inc
- 4.3.1 Eisai Inc Company Information
- 4.3.2 Eisai Inc Business Overview
- 4.3.3 Eisai Inc Levetiracetam Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Eisai Inc Levetiracetam Product Portfolio
- 4.3.5 Eisai Inc Recent Developments
- 4.4 Salubris Pharmaceuticals
- 4.4.1 Salubris Pharmaceuticals Company Information
- 4.4.2 Salubris Pharmaceuticals Business Overview
- 4.4.3 Salubris Pharmaceuticals Levetiracetam Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Salubris Pharmaceuticals Levetiracetam Product Portfolio
- 4.4.5 Salubris Pharmaceuticals Recent Developments
- 4.5 Sanofi
- 4.5.1 Sanofi Company Information
- 4.5.2 Sanofi Business Overview
- 4.5.3 Sanofi Levetiracetam Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Sanofi Levetiracetam Product Portfolio
- 4.5.5 Sanofi Recent Developments
- 4.6 Novartis
- 4.6.1 Novartis Company Information
- 4.6.2 Novartis Business Overview
- 4.6.3 Novartis Levetiracetam Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Novartis Levetiracetam Product Portfolio
- 4.6.5 Novartis Recent Developments
- 4.7 Pfizer
- 4.7.1 Pfizer Company Information
- 4.7.2 Pfizer Business Overview
- 4.7.3 Pfizer Levetiracetam Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Pfizer Levetiracetam Product Portfolio
- 4.7.5 Pfizer Recent Developments
- 4.8 GlaxoSmithKline
- 4.8.1 GlaxoSmithKline Company Information
- 4.8.2 GlaxoSmithKline Business Overview
- 4.8.3 GlaxoSmithKline Levetiracetam Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 GlaxoSmithKline Levetiracetam Product Portfolio
- 4.8.5 GlaxoSmithKline Recent Developments
- 4.9 UCB Pharma
- 4.9.1 UCB Pharma Company Information
- 4.9.2 UCB Pharma Business Overview
- 4.9.3 UCB Pharma Levetiracetam Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 UCB Pharma Levetiracetam Product Portfolio
- 4.9.5 UCB Pharma Recent Developments
5 Global Levetiracetam Market Scenario by Region
- 5.1 Global Levetiracetam Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Levetiracetam Sales by Region: 2021-2032
- 5.2.1 Global Levetiracetam Sales by Region: 2021-2026
- 5.2.2 Global Levetiracetam Sales by Region: 2027-2032
- 5.3 Global Levetiracetam Revenue by Region: 2021-2032
- 5.3.1 Global Levetiracetam Revenue by Region: 2021-2026
- 5.3.2 Global Levetiracetam Revenue by Region: 2027-2032
- 5.4 North America Levetiracetam Market Facts & Figures by Country
- 5.4.1 North America Levetiracetam Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Levetiracetam Sales by Country (2021-2032)
- 5.4.3 North America Levetiracetam Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Levetiracetam Market Facts & Figures by Country
- 5.5.1 Europe Levetiracetam Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Levetiracetam Sales by Country (2021-2032)
- 5.5.3 Europe Levetiracetam Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Levetiracetam Market Facts & Figures by Country
- 5.6.1 Asia Pacific Levetiracetam Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Levetiracetam Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Levetiracetam Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Levetiracetam Market Facts & Figures by Country
- 5.7.1 South America Levetiracetam Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Levetiracetam Sales by Country (2021-2032)
- 5.7.3 South America Levetiracetam Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Levetiracetam Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Levetiracetam Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Levetiracetam Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Levetiracetam Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Levetiracetam Sales by Type (2021-2032)
- 6.1.1 Global Levetiracetam Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Levetiracetam Sales Market Share by Type (2021-2032)
- 6.2 Global Levetiracetam Revenue by Type (2021-2032)
- 6.2.1 Global Levetiracetam Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Levetiracetam Revenue Market Share by Type (2021-2032)
- 6.3 Global Levetiracetam Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Levetiracetam Sales by Application (2021-2032)
- 7.1.1 Global Levetiracetam Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Levetiracetam Sales Market Share by Application (2021-2032)
- 7.2 Global Levetiracetam Revenue by Application (2021-2032)
- 7.2.1 Global Levetiracetam Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Levetiracetam Revenue Market Share by Application (2021-2032)
- 7.3 Global Levetiracetam Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Levetiracetam Value Chain Analysis
- 8.1.1 Levetiracetam Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Levetiracetam Production Mode & Process
- 8.2 Levetiracetam Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Levetiracetam Distributors
- 8.2.3 Levetiracetam Customers
9 Global Levetiracetam Analyzing Market Dynamics
- 9.1 Levetiracetam Industry Trends
- 9.2 Levetiracetam Industry Drivers
- 9.3 Levetiracetam Industry Opportunities and Challenges
- 9.4 Levetiracetam Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst